Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

HR leaders share how they're putting people first in an ever-changing workplace

HR professionals are navigating RTO, AI, cultural changes, and divisive virtual cultural issues.

Fortune

3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025

Hunting for value? These three Dividend Aristocrats look cheap by today's valuations.

Barchart

AbbVie's Q3 2024 Earnings: What to Expect

With AbbVie gearing up to release its third-quarter earnings later this month, analysts expect a marginal decline in earnings.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Highest-yielding Dividend Kings for Maximum Income and Stability

Looking for reliable yield? These three companies offer ever-increasing dividends and a lifetime of stability.

Barchart

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

3 Dividend Powerhouses, Including One With 7% Yield

By investing in these dividend powerhouses, investors can achieve reliable income, mitigate risk through diversification, and potentially enjoy capital gains.

Barchart

Is AbbVie Stock Outperforming the Nasdaq?

AbbVie has recently outperformed the Nasdaq, and Wall Street analysts are moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

3 Defensive Dividend Stocks to Scoop Up Now

Amid ongoing market uncertainty, Morgan Stanley believes these three defensive dividend-paying stocks could be ideal buys now.

Barchart

3 Safe High-Yield Dividend Stocks to Pounce on Now

In today's volatile market, dividend stocks remain one of the safest choices.

Barchart

Nervous About the Market? 3 Defensive Stock Picks to Consider This August

Explore three defensive stock picks from the consumer staples, healthcare, and utilities sectors that offer stability amid market uncertainty in August.

Barchart

Best Stocks to Buy for Fed Rate Cuts

The Federal Reserve cut rates again at its December meeting, and lower borrowing costs could boost these large-cap stocks.

Kiplinger

What Are Wall Street Analysts' Target Price for Abbvie Stock?

Despite AbbVie stock’s robust price performance compared to the broader market over the past year, Wall Street analysts are moderately bullish about the stock’s prospects.

Barchart

Secure Decades of Passive Income: 3 Top Dividend Stocks to Buy Now

These companies have consistently paid and increased their dividends, and they have a growing earnings base to support their future payouts.

Barchart

3 Highest-Yielding Dividend Kings That Wall Street Loves

A high yield doesn't necessarily translate to a buy. This article bridges the gap by combining high dividend payouts and buy ratings.

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Option Volatility And Earnings Report For July 22 - 26

This week we have Tesla (TSLA), Microsoft (MSFT), Alphabet (GOOGL), Exxon Mobil (XOM), Visa (V), Abbvie (ABBV) and Chipotle Mexican Grill (CMG) all set to report.

Barchart

AbbVie Earnings Preview: What to Expect

AbbVie is all set to announce its second-quarter results this month, and analysts forecast a double-digit decline in the company’s bottom-line figure.

Barchart

Is Abbvie Stock Underperforming the S&P 500?

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

Barchart

Down 14% from All-Time Highs, is This Dividend King a Buy on the Dip?

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Abbvie Stock: Is Wall Street Bullish or Bearish?

Although Abbvie stock has been lagging behind the broader market over the past year, Wall Street analysts are still moderately bullish about its outlook.

Barchart

3 Cheapest Dividend Kings To Buy Today

This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years.

Barchart

5 Standout Healthcare Dividend Stocks to Consider Now

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Barchart

Stock Index Futures Climb on Upbeat Big Tech Earnings, U.S. Inflation Data Looms

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

StockNews.com

Merck (MRK) vs. AbbVie (ABBV): Which Pharma Stock Will Drive Earnings Growth?

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

LiveScience

Fake Botox injections have sickened 22, hospitalized 11, CDC warns

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.

WEKU

Fake Botox has sickened patients nationwide. Here's what to know — and what to avoid

Public health authorities are investigating reports of counterfeit injections sickening 19 people across nine states. Experts say getting bona fide Botox starts with finding a trustworthy provider.

1 … 4 5 6 7

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.